Lesley Kelly

Lesley Kelly joined Venrock’s New York VHCP team in 2020 as Head Trader. In previous roles, she has traded healthcare on the buy-side and the sell-side–most recently joining from RBC Capital Markets. Prior to finance, Lesley served on active duty as an Intelligence Officer and Jumpmaster in the U.S. Army. She continues to support several Veteran philanthropies.

Lesley earned her B.S. from the University of Michigan, and an MBA from Owen Graduate School at Vanderbilt University.

Kole Roybal

Dr. Roybal is an Assistant Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He received his doctorate in Immunology from UT Southwestern Medical Center and was a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of Wendell A. Lim at UCSF and the Howard Hughes Medical Institute.

He is currently a member of the Parker Institute for Cancer Immunotherapy, the Helen Diller Family Comprehensive Cancer Center, and an inaugural Chan Zuckerberg Biohub Investigator. He is also the Deputy Director of the UCSF Center for Synthetic Immunology recently funded by the Cancer Moonshot Initiative. He was awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award in 2018.

The Roybal lab harnesses the tools of Synthetic Biology and Immunology to control and customize immune cell therapeutics for cancer and autoimmunity. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist. Cell Design Labs was acquired by Gilead at the end of 2017. He was also instrumental in developing universal CAR T cell technology in collaboration with Xyphos Biosciences, which was acquired by Astellas at the end of 2019.  He has now co-founded Arsenal Biosciences, which focuses on building cellular therapies for solid tumors with a combination of cutting-edge synthetic biology and gene editing technologies.

Mathai Mammen

As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity.  The team works across a wide range of therapeutic areas and biological pathways.  Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality.  The team is invested deeply in data sciences in every aspect of R&D.  Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world.

Prior to Janssen, Mathai was SVP at Merck Research Laboratories, and with his team he initiated numerous new programs and progressed eight into early clinical development.  At Theravance, a company he co-founded in 1997 based on his work at Harvard University, his talented team nominated 31 development candidates and created five approved products.

Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry.

Todd Park

Todd Park is Co-Founder and Executive Chairman of Devoted Health, a company focused on dramatically improving health care for seniors.  Prior to Devoted Health, Todd served as White House technology advisor based in Silicon Valley until January 2017, a role in which he focused on bringing top technology talent and best practices into government to improve service delivery, national defense, public engagement, and more.  Prior to this role, Todd served from March 2012 to August 2014 as U.S. Chief Technology Officer in the White House Office of Science and Technology Policy and, in that position, served as an Assistant to the President.  Todd joined the Obama Administration in August 2009 as Chief Technology Officer of the U.S. Department of Health and Human Services (HHS), where he functioned as an “entrepreneur-in-residence,” helping HHS harness the power of data, technology, and innovation to improve the health of the nation.  For his work at HHS, Todd was named one of Fast Company’s “100 Most Creative People in Business” in 2010.

Prior to his work in government, Todd co-founded Athenahealth in 1997 and co-led its development over more than a decade into a leading provider of cloud-based software and services for physicians and health care practitioners. He also co-founded Castlight Health, an innovative online health benefits platform company, in 2008, and has served as a senior advisor to Ashoka, a global incubator of social entrepreneurs, where he helped start a venture to bring affordable telehealth, drugs, diagnostics, and clean water to rural India.

Todd graduated magna cum laude and Phi Beta Kappa from Harvard College with an A.B. in Economics.  He currently serves on the boards of New America and the Biden Cancer Initiative and on the Obama Foundation’s Digital & Technology Council.  Todd was elected a Fellow of the National Academy of Public Administration in 2017 and is a member of the 2017 Class of Henry Crown Fellows within the Aspen Global Leadership Network at the Aspen Institute.

John Stuelpnagel

John joined the Venrock family in 1998, shortly after co-founding Illumina (Nasdaq: ILMN) and convincing Bryan to make it his first investment. John was Illumina’s first CEO, and most recently its COO. After leaving Illumina, John co-founded Ariosa (a Venrock portfolio company), serving as its Executive Chairman until its acquisition by Roche. In addition, John was the Chairman at Sequenta until its acquisition by Adaptive (Nasdaq: ADPT). Currently, John is Chairman at the following Venrock portfolio companies: 10x Genomics (Nasdaq: TXG), Inscripta, and Element Biosciences, and also serves on the Board of Directors for Encoded Therapeutics. He is also the Chairman at Fabric Genomics.

John has a BS and a DVM from the University of California, Davis and an MBA from the University of Los Angeles.

Julie Park

Julie joined Venrock in 2020 and focuses on investments in the consumer, commerce, and SMB tools & services sectors.

Most recently, Julie was an executive at Facebook, where she helped SMBs grow as director of the global long tail ads business. Prior, she was on the founding product and sales teams at Pinterest. Before moving to the west coast, Julie was a vice president at Goldman Sachs, where she worked closely with consumer and retail brands.

Julie has dual degrees from Stanford, with a Master of Science from the School of Engineering.

Inside and outside the office, Julie is fascinated by emerging trends that shape how we eat, work, travel, and play. You can follow her on twitter at https://twitter.com/juliehpark. 

Mariana Mihalusova

Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over a dozen drugs across a diverse set of disease areas (hematology, oncology, inflammation/immunology, neurodegenerative diseases) and modalities (small molecules, biologics, engineered cell therapies).

Mariana received her Ph.D. in Biochemistry from Harvard University, MBA from Harvard Business School, and Sc.B. in Biochemistry from Brown University.

Todd Graham

Todd is based in our Palo Alto Office where he focuses primarily on enterprise infrastructure and cybersecurity. He is very passionate about the intersection of technology and business. His main areas of interest include digital transformation, human-based threats, disruptive go-to-market, and the consumerization of the user experience.

In his career, Todd has alternated between startups and large infrastructure vendors. Most recently, he led Corporate Strategy for Cisco’s Security and Collaboration businesses where he developed long-range business strategy for product and go to market while also driving inorganic activities such as the acquisition of Duo Security. Earlier in his career, he led the IT Business Management product group at VMware. Using experience gained at VMware, Todd co-founded Bluenose Analytics to help product and customer success leaders better familiarize with their customers. He also founded a Data Loss Prevention company that was acquired by EMC’s security division, RSA, while attending the University of Michigan (Go Blue!).

Outside of work, Todd can be found with his family exploring the wilds of San Francisco, attending youth soccer games, and celebrating children’s birthdays. In what remains of his spare time, he enjoys carpentry, coding, and all things Canadian.

Harry Barber

Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group.

Prior to business school, Harry spent two years practicing as a Physician in the UK’s National Health Service. During this time he published a number of research articles in peer-reviewed journals. He received his medical degree and bachelors from University College London where he graduated with First Class honors, on the Dean’s List.

Andrew Gottesdiener

Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to medical school, Andrew worked in the Appel Alzheimer’s Disease Research Institute at Weill Cornell where he was developing preclinical gene therapy platforms to treat Alzheimer’s disease.

Andrew earned his AB in Economics from Washington University in St. Louis, where he graduated with College Honors and spent three years in the lab of Dr. David Holtzman studying the mechanisms of Alzheimer’s disease pathogenesis.